A small, but growing body of evidence is starting to correlate the physiologic adrenal suppression of etomidate with worsening clinical outcomes. This study is a French prospective cohort that really likes etomidate for RSI, so, they decided to ask the question whether a continuous hydrocortisone infusion has any substantial effect on cardiovascular parameters in the setting of etomidate use.
Short answer, no.
Their randomized groups are awfully small - 45 patients in each group - so their power to detect a difference is not great. But, at the minimum, there's no profoundly obvious difference or any seemingly clinically significant trend between the two groups.
I trained using etomidate for everyone, but I've almost completely moved to alternative agents, ketamine being the most prominent of those agents. Most significantly, ketamine differs from the other agents in terms of having analgesic properties as well, and I think it is reasonable to provide some treatment for the pain associated with laryngoscopy. There is evidence that ketamine is a myocardial depressant and may be deleterious in patients with limited cardiac reserve, but so far in limited literature it holds up clinically well against etomidate and midazolam.
"Corticosteroid after etomidate in critically ill patients: A randomized controlled trial"
"Intubating ICU patients with ketamine: adverse effects that can occur."